Streetbeat News

Revenues

BRDG

Bridge Investment Group (NYSE:BRDG) received varied analyst ratings over the last quarter, with a shift towards a somewhat bullish stance in the last 30 days. Analysts from Morgan Stanley, Wells Fargo, JP Morgan, and TD Cowen have adjusted their price targets, reflecting a decrease in the average 12-month price target from $12.83 to $11.12. The company's financial performance shows challenges in revenue growth, net margin, ROE, ROA, and debt management, indicating potential difficulties ahead.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:01 pm

LRCX

The article provides an in-depth analysis of Lam Research (LRCX) and its competitors within the Semiconductors & Semiconductor Equipment industry, focusing on financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Lam Research is highlighted for its market leadership in etch and second in deposition, significant exposure to memory chipmakers, and strong financial performance despite a revenue growth concern.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

CCCC

C4 Therapeutics (NASDAQ:CCCC) has received mixed analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. Analysts have updated their price targets, indicating a significant increase in the average target to $9.75, up 95% from the previous $5.00. The company has shown a strong revenue growth rate of 63.93% as of September 30, 2023, but trails behind its peers in the Health Care sector. Despite a high net margin of -244.19% and impressive ROE and ROA figures, C4 Therapeutics's market capitalization remains below the industry average.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

FLNC

Fluence Energy (NASDAQ:FLNC) has received mixed analyst ratings over the past three months, with an average 12-month price target of $27.73, up 5.44% from the previous target. Analysts' actions range from maintaining to raising their ratings and price targets, reflecting varying perspectives on the company's performance and market position. Fluence Energy's financial performance shows positive revenue growth but challenges in net margin, ROE, and ROA, with a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

EGLE

Eagle Bulk Shipping (NYSE:EGLE) has been evaluated by 4 analysts over the last three months, with all maintaining an indifferent stance. The average 12-month price target for EGLE has been adjusted to $53.55, down from $63.00, indicating a 15.0% decrease. The company's financial performance shows challenges in revenue growth, profitability, and debt management, with a notable revenue decline of -55.42% over the past 3 months and below-average net margin and ROE.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

ESS

Essex Property Trust (NYSE:ESS) has received mixed analyst ratings over the past quarter, with a total of 9 analysts offering diverse opinions. The recent assessments show a shift towards a more neutral stance in the last 30 days compared to previous months. Analysts have updated their price targets, with the current average target at $246.33, marking a 4.49% increase from the previous average of $235.75. The company's financial performance indicates strong market confidence, with notable revenue growth, net margin, ROE, and ROA, despite lagging behind industry peers in revenue growth rate.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

ELAN

Elanco Animal Health Inc (NYSE:ELAN) reported Q4 2023 revenue of $1.035 billion, a 5% increase, surpassing consensus estimates. Adjusted EPS was $0.08, missing expectations and down 59% Y/Y. Pet Health revenue declined by 1%, while Farm Animal revenue grew by 10%. The company announced a restructuring impacting 420 personnel, aiming for annualized savings. FY 2024 sales are forecasted between $4.45 billion and $4.54 billion, with adjusted EPS of $0.87-$0.95. ELAN shares dropped 0.58% to $16.28.

Portfolio Pulse from Vandana Singh

February 26, 2024 | 3:54 pm

SPY

The Dallas Fed Texas Manufacturing Output Index for February showed a reading of 1, compared to -15.4 in the previous month, indicating a significant improvement in manufacturing output in Texas.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 3:32 pm

ZVSA

ZyVersa Therapeutics Inc (NASDAQ:ZVSA) shares surged 126% to $1.81 without specific company news, following volatility after releasing a white paper on Inflammasome ASC Inhibitor IC 100's potential for neurological diseases. The company plans to file an IND in late 2024 and start a phase 1 trial in early 2025.

Portfolio Pulse from Henry Khederian

February 26, 2024 | 3:04 pm

SFIX

Analyst reviews for Stitch Fix (NASDAQ:SFIX) over the past three months show a consensus of indifference, with all 5 analysts giving neutral ratings. The average 12-month price target is set at $3.8, indicating a slight decrease from the previous target of $3.88. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their reaction to the company's performance and market conditions. Stitch Fix's financial performance shows challenges, with a -17.79% decline in revenue growth and below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 3:01 pm